


Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma

Graphical abstract



Highlights

- Mortality from intrahepatic cholangiocarcinoma (ICC) tended to rise globally.
- Mortality from extrahepatic cholangiocarcinoma (ECC) decreased in most countries.
- Mortality rates were around 1–2/100,000 for ICC and below 1/100,000 for ECC in most countries.
- The rise in ICC mortality is due to increased incidence.
- The fall in ECC mortality is due to laparoscopic cholecystectomy.

Authors

Paola Bertuccio, Matteo Malvezzi, Greta Carioli, ..., Hashem B. El-Serag, Carlo La Vecchia, Eva Negri

Correspondence

paola.bertuccio@unimi.it
(P. Bertuccio)

Lay summary

Biliary tract cancers include intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC), however there are some differences in their risk factors. Consequently, the distinction between ICC and ECC is important. Over the last few decades, mortality from ICC has tended to rise in several areas of the world, following the increased prevalence of its major risk factors. In contrast, mortality from ECC tended to decrease in most countries, following the increased use of laparoscopic cholecystectomy.



Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma

Paola Bertuccio^{1,*}, Matteo Malvezzi², Greta Carioli², Dana Hashim³, Paolo Boffetta^{3,4}, Hashem B. El-Serag^{5,6}, Carlo La Vecchia², Eva Negri¹

¹Department of Biomedical and Clinical Sciences, Università degli Studi di Milano, Milan, Italy; ²Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy; ³Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; ⁴Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy; ⁵Section of Gastroenterology and Hepatology, Department of Medicine, Michael E. DeBakey Veterans Affairs Medical Center and Baylor College of Medicine, Houston, TX Center, Houston, TX, USA; ⁶Center for Innovations in Quality, Effectiveness and Safety (IQEST), Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USA

Background & Aims: Intrahepatic (ICC) and extrahepatic cholangiocarcinoma (ECC) have rarely been studied individually, probably due to difficulties in their diagnosis and certification. Mortality trends from these 2 neoplasms have been inconsistent over the last decades. The aim of this study was to analyze worldwide trends in mortality from ICC and ECC in selected countries.

Methods: We extracted death certification data for ICC and ECC, and population estimates from the World Health Organization and Pan American Health Organization databases for 32 selected countries from Europe, the Americas, and Australasia from 1995 to 2016. We computed age-standardized (world population) mortality rates from ICC and ECC, and performed joint regression analysis.

Results: Mortality rates from ICC increased in all countries considered, with a levelling off over recent years in Germany (women), Italy (men), Argentina (men), the USA (men), Hong Kong (men), and Japan (both sexes). The highest rates in 2010–2014 (1.5–2.5/100,000 in men and 1.2–1.7/100,000 in women) were registered in Hong Kong, France, Austria, Spain, the UK, and Australia. The lowest rates (0.2–0.6/100,000 in both sexes) were registered in Latin American and eastern European countries. Mortality from ECC decreased in most of the countries considered, with rates below 1/100,000 in both sexes between 2010 and 2014, with the only exception being Japan (2.8/100,000 in men and 1.4/100,000 in women).

Conclusions: Increasing mortality from ICC was observed globally, due to trends in risk factors and possibly, in part, due to better disease classification. Mortality from ECC levelled off or decreased, most likely following the increased use of laparoscopic cholecystectomy.

Lay summary: Biliary tract cancers include intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC), however there are some differences in their risk factors.

Consequently, the distinction between ICC and ECC is important. Over the last few decades, mortality from ICC has tended to rise in several areas of the world, following the increased prevalence of its major risk factors. In contrast, mortality from ECC tended to decrease in most countries, following the increased use of laparoscopic cholecystectomy.

© 2019 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Introduction

Cholangiocarcinoma is the second most common primary liver neoplasm after hepatocellular carcinoma.^{1,2} These neoplasms arise from the epithelial cells of the biliary tree, commonly classified as intrahepatic cholangiocarcinoma (ICC) if they arise above the hilar junction of bile ducts or extrahepatic cholangiocarcinoma (ECC) if they arise within or below the hilum.

These 2 types of cancer have some recognized differences in risk factors and clinical presentation.^{3–6} However, ICC and ECC have rarely been studied comparatively, possibly due to difficulties in their diagnosis, registration and certification.^{7–9} However, the validity of death certification for these neoplasms has improved in recent years.^{8,9}

Still, mortality trends from ICC and ECC have been inconsistent over the last decades^{10–12}. Therefore, in this work, we aim to analyze recent mortality trends from ICC and ECC in countries with valid data.

Materials and methods

We extracted official death certification data for ICC and ECC from the World Health Organization (WHO) database, as available on electronic support,¹³ between 1995 and 2016, when the Tenth Revision of the International Classification of Diseases (ICD-10) was used (ICD-10 code C22.1 for ICC, and C24.0 for ECC).¹⁴ Gallbladder cancer (ICD-10 code C23) was not included. Histological codes were not available.

We analyzed data for 18 European countries, 16 of which belonged to the European Union, 9 countries from the Americas, and 5 countries from Australasia. We selected these countries because they reported consistent and valid data, according to

Keywords: Intrahepatic cholangiocarcinoma; Extrahepatic cholangiocarcinoma; Mortality; Trends; Worldwide.

Received 25 January 2019; received in revised form 12 March 2019; accepted 18 March 2019; available online 23 March 2019

* Corresponding author. Address: Department of Biomedical and Clinical Sciences, Università degli Studi di Milano, Via Vanzetti 5, 20122 Milan, Italy. Tel.: +39 02 503 20854; fax: +39 02 503 20866.

E-mail address: paola.bertuccio@unimi.it (P. Bertuccio).



Table 1. Age-standardized (world population) mortality rates from ICC and ECC per 100,000 person-years at all ages, according to sex and selected countries.

	ICC					ECC				
	2002	2007	2012	Average deaths	% change (2012/02)	2002	2007	2012	Average deaths	% change (2012/02)
Men										
European Union										
Austria (2002–2004)	1.31	1.51	1.75	146	33.6	0.85	0.68	0.66	59	–22.4
Belgium	0.85	1.07	1.35	154	58.8	0.07	0.08	0.12	16	71.4
Croatia	0.47	0.70	1.02	42	117.0	0.57	0.56	0.63	28	10.5
Czech Republic	0.43	0.49	0.60	57	39.5	0.39	0.42	0.52	51	33.3
Denmark	0.41	0.54	0.78	43	90.2	0.28	0.18	0.13	8	–53.6
Finland	1.13	1.22	1.04	58	–8.0	0.32	0.36	0.30	18	–6.3
France	1.04	1.39	1.78	1143	71.2	0.09	0.09	0.07	55	–22.2
Germany	0.64	1.06	1.15	1062	79.7	0.56	0.50	0.70	702	25.0
Hungary	0.28	0.27	0.48	38	71.4	0.87	0.36	0.69	61	–20.7
Italy (2003–2004)	0.57	0.78	1.00	689	75.4	0.29	0.25	0.21	172	–27.6
Lithuania (2001–2004)	0.36	0.41	0.62	16	72.2	0.52	0.35	0.28	8	–46.2
Netherlands	0.58	0.63	0.91	149	56.9	0.43	0.42	0.41	65	–4.7
Portugal (2002–2003/2007–2009)	0.78	0.94	1.40	156	79.5	0.49	0.57	0.36	43	–26.5
Spain	0.95	1.31	1.69	818	77.9	0.06	0.05	0.09	48	50.0
Sweden	0.42	0.49	0.68	68	61.9	0.62	0.59	0.54	58	–12.9
UK	0.84	1.24	1.55	1029	84.5	0.07	0.07	0.05	38	–28.6
UK, England and Wales (2001–2004)	0.98	1.22	1.55	914	58.2	0.08	0.06	0.05	33	–37.5
UK, Northern Ireland (2001–2004)	1.35	1.38	1.61	26	19.3	0.30	0.15	0.10	2	–66.7
UK, Scotland	1.26	1.41	1.59	89	26.2	0.10	0.07	0.06	4	–40.0
Other European countries										
Norway	0.36	0.73	1.06	46	194.4	0.20	0.10	0.07	3	–65.0
Switzerland	0.83	1.19	1.23	98	48.2	0.32	0.24	0.32	28	0.0
American countries										
Argentina	0.08	0.09	0.23	55	187.5	0.09	0.07	0.04	11	–55.6
Brazil	0.19	0.26	0.35	334	84.2	0.40	0.38	0.34	324	–15.0
Canada (2010–2013)	0.80	1.03	1.38	449	72.5	0.18	0.11	0.07	26	–61.1
Chile	0.22	0.38	0.50	54	127.3	0.15	0.13	0.09	10	–40.0
Colombia	0.32	0.49	0.55	112	71.9	0.12	0.11	0.09	18	–25.0
Mexico	0.36	0.38	0.44	226	22.2	0.09	0.08	0.05	26	–44.4
Puerto Rico	0.57	0.53	0.74	21	29.8	0.10	0.08	0.06	2	–40.0
USA	0.73	0.84	1.04	2693	42.5	0.16	0.12	0.11	307	–31.3
Venezuela (2010–2013)	0.27	0.30	0.35	42	29.6	0.09	0.05	0.05	7	–44.4
Australasian countries										
Hong Kong SAR (2001–2004)	2.40	2.49	2.50	180	4.2	0.18	0.10	0.10	7	–44.4
Israel	0.76	0.90	0.97	50	27.6	0.07	0.05	0.04	3	–42.9
Japan	1.08	1.09	1.10	1916	1.9	3.15	2.99	2.81	5694	–10.8
Australia (2006–2009)	0.94	1.27	1.52	315	61.7	0.20	0.10	0.08	19	–60.0
New Zealand (2010–2013)	0.70	1.26	1.08	42	54.3	0.32	0.22	0.22	9	–31.3
Women										
European Union										
Austria (2002–2004)	0.88	1.07	1.16	138	31.8	0.64	0.53	0.47	58	–26.6
Belgium	0.75	0.87	1.05	157	40.0	0.07	0.04	0.07	15	0.0
Croatia	0.20	0.43	0.72	43	260.0	0.37	0.32	0.38	27	2.7
Czech Republic	0.27	0.36	0.42	53	55.6	0.43	0.38	0.34	51	–20.9
Denmark	0.31	0.55	0.76	52	145.2	0.19	0.22	0.20	14	5.3
Finland	0.96	1.03	0.82	66	–14.6	0.24	0.26	0.26	23	8.3
France	0.59	0.86	1.04	953	76.3	0.06	0.05	0.05	61	–16.7

Germany	0.46	0.72	0.82	1010	78.3	0.50	0.38	0.53	764	6.0
Hungary	0.21	0.19	0.30	39	42.9	0.62	0.30	0.56	79	-9.7
Italy (2003–2004)	0.41	0.52	0.67	625	63.4	0.21	0.16	0.13	171	-38.1
Lithuania (2001–2004)	0.23	0.30	0.61	27	165.2	0.36	0.26	0.20	10	-44.4
Netherlands	0.43	0.46	0.68	138	58.1	0.34	0.32	0.33	71	-2.9
Portugal (2002–2003/2007–2009)	0.43	0.49	0.75	119	74.4	0.43	0.32	0.25	43	-41.9
Spain	0.60	0.80	0.98	701	63.3	0.04	0.03	0.04	39	0.0
Sweden	0.38	0.39	0.66	78	73.7	0.66	0.75	0.61	84	-7.6
UK	0.73	1.12	1.46	1236	100.0	0.06	0.05	0.04	39	-33.3
UK, England and Wales (2001–2004)	0.84	1.11	1.45	1090	72.6	0.07	0.05	0.04	36	-42.9
UK, Northern Ireland (2001–2004)	1.21	1.29	1.36	29	12.4	0.11	0.07	0.07	2	-36.4
UK, Scotland	1.26	1.17	1.57	117	24.6	0.11	0.07	0.03	2	-72.7
Other European countries										
Norway	0.35	0.76	1.00	54	185.7	0.18	0.05	0.05	3	-72.2
Switzerland	0.73	0.90	1.00	103	37.0	0.31	0.25	0.30	34	-3.2
American countries										
Argentina	0.06	0.07	0.16	52	166.7	0.09	0.09	0.02	10	-77.8
Brazil	0.19	0.28	0.36	432	89.5	0.53	0.51	0.42	527	-20.8
Canada (2010–2013)	0.60	0.83	1.19	465	98.3	0.13	0.08	0.07	35	-46.2
Chile	0.22	0.33	0.45	64	104.5	0.15	0.12	0.09	13	-40.0
Colombia	0.46	0.69	0.69	177	50.0	0.20	0.14	0.09	23	-55.0
Mexico	0.46	0.57	0.61	351	32.6	0.14	0.11	0.07	44	-50.0
Puerto Rico	0.35	0.33	0.48	19	37.1	0.09	0.06	0.07	3	-22.2
USA	0.56	0.66	0.82	2615	46.4	0.11	0.09	0.08	297	-27.3
Venezuela (2010–2013)	0.34	0.33	0.37	51	8.8	0.15	0.07	0.06	8	-60.0
Australasian countries										
Hong Kong SAR (2001–2004)	1.62	1.66	1.71	148	5.6	0.13	0.06	0.05	4	-61.5
Israel	0.46	0.77	0.86	58	87.0	0.07	0.04	0.05	4	-28.6
Japan	0.58	0.58	0.57	1398	-1.7	1.71	1.53	1.37	4682	-19.9
Australia (2006–2009)	0.76	1.02	1.23	305	61.8	0.14	0.08	0.05	15	-64.3
New Zealand (2010–2013)	0.62	0.96	0.98	46	58.1	0.25	0.15	0.15	8	-40.0

Data from 2002 (2000–2004), 2007 (2005–2009) and 2012 (2010–2014) (unless indicated in parentheses). The average number of deaths from the latest period and the corresponding change in rates are provided, according to sex and selected countries. ECC, extrahepatic cholangiocarcinoma; ICC, intrahepatic cholangiocarcinoma.

the WHO guidelines,^{15,16} i.e. all countries considered had over 2 million inhabitants and death certification coverage was above 85%.

We extracted estimates of the resident population, based on official censuses, from the same WHO database.¹³ For American countries, since data were unavailable in the WHO database for several years, we extracted the populations from the Pan American Health Organization database.¹⁷

From the matrices of certified deaths and resident populations, we computed age-specific rates for each 5-year age group (from 0–4 to 85+ years, and from 0–4 to 80+ years for American countries), sex, and calendar year. We then computed age-standardized mortality rates per 100,000 person-years at all ages and for those aged 45–64 years, using the direct method of standardization based on the 1960 world standard population.¹⁸

For 24 countries with a population greater than 10 million or annual average number of deaths greater than 200 in the last quinquennium, we performed a joinpoint regression analysis for ICC mortality during the period (1995–2016). We thus identified the years when a significant change in the linear slope of the temporal trend (on a log scale) occurred, by testing from 0 up to a maximum of 3 inflection points (called “joinpoints”).^{19,20} The estimated annual percentage change (APC) was then computed for each of the identified trends by fitting a regression line to the natural logarithm of the rates using calendar year as a regressor variable.

Results

Table 1 shows age-standardized mortality rates from ICC and ECC per 100,000 person-years, at all ages, for 2002 (2000–2004), 2007 (2005–2009), and 2012 (2010–2014), according to sex and country. In addition, Table 1 shows the annual average number of deaths of the more recent period, and the corresponding percentage change in rates between 2012 and 2002, according to sex and country.

Mortality rates from ICC were consistently below 1/100,000 among men in the early 2000s in most countries. Between 2002 and 2012, mortality increased in all countries except in Finland. The highest incremental changes were observed in Norway, Croatia, Denmark, the UK, Germany, and Portugal among European countries, in Argentina, Chile, and Brazil among American countries, and in Australia. As a result, in the 2010–2014 period, mortality rates from ICC in men were between 1–2/100,000 person-years in most countries (Fig. 1). The highest mortality rates were in Hong Kong (2.5/100,000 in men), and in France, Austria, Spain, the UK, and Australia (between 1.5 and 1.8/100,000 in men). The lowest rates (0.2 and 0.5/100,000) were registered in the Latin American countries considered. ICC rates were 1.04/100,000 for men in the USA, and 1.1/100,000 in Japan. The differences in rates across countries were highly significant.

The mortality patterns were similar in women, although they had generally lower mortality rates than men. Mortality rates from ICC increased in all countries, except in Finland (–15%)




Fig. 1. Age-standardized (world population) mortality rates from ICC in men and women. Data from 32 countries worldwide during the 2010–2014 quinquennium (when available). ICC, intrahepatic cholangiocarcinoma.




Fig. 2. Age-standardized (world population) mortality rates from ECC in men and women. Data from 32 countries worldwide during the 2010–2014 quinquennium (when available). ECC, extrahepatic cholangiocarcinoma.

and Japan (−1.7%). The highest percentage changes were observed in Croatia, Norway, Lithuania, Denmark, the UK, Argentina, and Chile. The highest mortality rates over 1/100,000 women were registered in Hong Kong (1.7), the UK (1.5), Australia, Canada, and Austria (around 1.2), Belgium, France, Switzerland, and Norway (around 1). The lowest rates (below 0.5/100,000 women) were observed in Argentina (0.2), Hungary (0.3), Brazil, Venezuela, and the Czech Republic (around 0.4), Chile and Puerto Rico (almost 0.5). ICC rates in the USA were 0.8/100,000 women, and 0.6/100,000 in Japan (Fig. 1).

With reference to ECC, rates of 0.5–0.9/100,000 in the early 2000s were observed in Lithuania (about 0.5/100,000 men), Croatia, Germany, Sweden (around 0.6), Austria and Hungary (almost 0.9). Japan had a mortality rate of 3.2/100,000 men around 2002. Over the last decade, ECC rates decreased in most countries. In 2010–2014, mortality from ECC showed rates below 1/100,000 men in all countries, with the only exception being Japan (2.8/100,000 men, Fig. 2). The lowest rates below 0.1/100,000 men were observed in some central and northern European countries, in Canada and most Latin American countries, in Israel, and in Australia.

Mortality rates from ECC decreased in women, too, in most countries. The highest rates in 2010–2014 were registered in Japan (1.4/100,000), followed by Austria, Germany, and other central European countries (Fig. 2).

Table 2 shows the age-standardized mortality rates at 45–64 years of age. For ICC, male mortality rates showed substantial increases over the last decade with rates that varied between 2

and 3/100,000 men. In 2010–2014, the highest mortality rates were observed in Hong Kong (3.7/100,000), and in Austria, France and Spain (around 3/100,000). The lowest rates were registered in Latin American countries. For ECC, mortality rates were below 1/100,000 in all countries, with the exception of Japan (3.1/100,000 men), Hungary (1.4) and Germany (1.0). Also, in middle-aged women, upward trends were observed for ICC. In 2010–2014, ICC rates varied around 1–2/100,000 person-years. In contrast, mortality from ECC in women aged 45 to 64 years old declined in most countries, with rates below 0.4/100,000, and only a few countries showing rates between 0.5–1.0/100,000.

Fig. 3 and Table 3 report the joinpoint regression analysis results on mortality trends from ICC. Upward trends were observed in most countries. The APC in Europe varied between 2% in the Czech Republic and 7.6% in Portugal for the whole period. There were substantial early increases in Germany and Italy, followed by a levelling off thereafter. In the Americas the highest increases were in Chile and Argentina. Rising mortality trends until 2013 in the USA slowed down in recent years. Hong Kong showed stable rates followed by a marked decrease in the most recent years, whereas in Japan they were upward until the early 2000s and stable thereafter.

Discussion

This work showed global increases in mortality from ICC, and declines from ECC for both sexes, in most countries providing acceptable data reliability. It also shows substantial variations,

Table 2. Age-standardized (world population) mortality rates from ICC and ECC per 100,000 person-years in the age group 45–64, according to sex and selected countries.

	ICC					ECC				
	2002	2007	2012	Average deaths	% change (2012/02)	2002	2007	2012	Average deaths	% change (2012/02)
Men										
European Union										
Austria (2002–2004)	2.57	3.03	3.30	38	28.4	1.03	0.95	0.92	10	-10.7
Belgium	1.42	2.21	2.36	36	66.2	0.08	0.14	0.15	2	87.5
Croatia	0.91	1.42	1.56	10	71.4	0.65	0.60	0.91	6	40.0
Czech Republic	0.92	1.31	1.18	19	28.3	0.64	0.66	0.83	13	29.7
Denmark	0.91	1.12	1.36	11	49.5	0.40	0.32	0.17	1	-57.5
Finland	2.43	2.61	1.85	16	-23.9	0.43	0.52	0.36	3	-16.3
France	2.27	2.58	3.25	285	43.2	0.11	0.14	0.08	7	-27.3
Germany	1.30	2.01	2.16	260	66.2	0.91	0.80	1.01	122	11.0
Hungary	0.69	0.60	1.28	17	85.5	1.49	0.66	1.36	19	-8.7
Italy (2003–2004)	1.22	1.57	1.95	163	59.8	0.36	0.29	0.22	18	-38.9
Lithuania (2001–2004)	1.18	0.91	1.36	5	15.3	1.32	0.72	0.28	1	-78.8
Netherlands	1.03	1.10	1.56	39	51.5	0.89	0.67	0.74	18	-16.9
Portugal (2002–2003/2007–2009)	1.61	1.87	2.53	36	57.1	0.47	1.16	0.52	7	10.6
Spain	1.55	2.33	2.93	175	89.0	0.13	0.06	0.13	8	0.0
Sweden	1.01	1.00	1.20	16	18.8	1.09	0.93	0.86	11	-21.1
UK	1.47	1.94	2.49	206	69.4	0.07	0.13	0.07	6	0.0
UK, England and Wales (2001–2004)	1.73	1.92	2.51	184	45.1	0.08	0.12	0.08	6	0.0
UK, Northern Ireland (2001–2004)	1.89	2.68	2.64	6	39.7	0.42	0.19	0.00	0	-100.0
UK, Scotland	2.25	1.85	2.19	16	-2.7	0.07	0.17	0.05	0	-28.6
Other European countries										
Norway	0.82	1.29	2.22	15	170.7	0.31	0.10	0.19	1	-38.7
Switzerland	1.58	2.57	2.29	26	44.9	0.51	0.48	0.42	5	-17.6
American countries										
Argentina	0.16	0.14	0.51	20	218.8	0.16	0.08	0.05	2	-68.8
Brazil	0.35	0.48	0.70	128	100.0	0.60	0.63	0.59	109	-1.7
Canada (2010–2013)	1.33	1.68	2.24	113	68.4	0.25	0.15	0.10	5	-60.0
Chile	0.40	0.68	0.81	15	102.5	0.29	0.21	0.17	3	-41.4
Colombia	0.55	0.82	0.88	37	60.0	0.24	0.18	0.11	4	-54.2
Mexico	0.62	0.66	0.79	72	27.4	0.15	0.11	0.09	8	-40.0
Puerto Rico	1.21	0.93	1.29	5	6.6	0.12	0.00	0.12	1	0.0
USA	1.42	1.65	2.08	885	46.5	0.22	0.19	0.18	79	-18.2
Venezuela (2010–2013)	0.42	0.61	0.77	18	83.3	0.10	0.08	0.05	1	-50.0
Australasian countries										
Hong Kong SAR (2001–2004)	3.20	3.66	3.72	40	16.3	0.27	0.07	0.10	1	-63.0
Israel	1.20	1.45	1.67	13	39.2	0.14	0.03	0.05	0	-64.3
Japan	1.99	1.95	1.91	374	-4.0	3.97	3.49	3.12	630	-21.4
Australia (2006–2009)	1.56	2.04	2.48	73	59.0	0.27	0.16	0.08	2	-70.4
New Zealand (2010–2013)	1.02	2.16	2.22	13	117.6	0.44	0.34	0.44	3	0.0
Women										
European Union										
Austria (2002–2004)	1.84	2.01	2.19	26	19.0	1.15	0.75	0.74	9	-35.7
Belgium	1.12	1.50	2.05	32	83.0	0.05	0.01	0.09	1	80.0
Croatia	0.35	0.72	1.50	10	328.6	0.76	0.33	0.57	4	-25.0
Czech Republic	0.53	0.68	0.80	13	50.9	0.78	0.51	0.53	9	-32.1
Denmark	0.45	1.26	1.34	11	197.8	0.39	0.31	0.37	3	-5.1
Finland	1.88	1.91	1.38	12	-26.6	0.21	0.35	0.45	4	114.3
France	1.00	1.65	1.93	179	93.0	0.06	0.06	0.05	5	-16.7

Germany	0.82	1.28	1.58	193	92.7	0.73	0.57	0.89	109	21.9
Hungary	0.41	0.45	0.66	11	61.0	1.03	0.59	1.04	16	1.0
Italy (2003–2004)	0.84	0.98	1.19	106	41.7	0.30	0.22	0.10	9	-66.7
Lithuania (2001–2004)	0.53	0.58	1.26	6	137.7	0.71	0.44	0.25	1	-64.8
Netherlands	0.79	0.76	1.30	32	64.6	0.49	0.47	0.60	15	22.4
Portugal (2002–2003/2007–2009)	0.92	0.77	1.26	20	37.0	0.72	0.33	0.41	6	-43.1
Spain	0.83	1.22	1.53	96	84.3	0.04	0.04	0.04	2	0.0
Sweden	0.85	0.70	1.19	15	40.0	1.29	1.37	0.81	11	-37.2
UK	1.32	1.94	2.46	212	86.4	0.08	0.08	0.06	5	-25.0
UK, England and Wales (2001–2004)	1.50	1.91	2.48	188	65.3	0.08	0.08	0.06	4	-25.0
UK, Northern Ireland (2001–2004)	1.97	2.51	2.06	5	4.6	0.11	0.00	0.15	0	36.4
UK, Scotland	2.30	2.03	2.45	19	6.5	0.22	0.08	0.03	0	-86.4
Other European countries										
Norway	0.53	1.33	1.87	12	252.8	0.36	0.03	0.07	0	-80.6
Switzerland	1.09	1.54	1.77	20	62.4	0.50	0.48	0.54	6	8.0
American countries										
Argentina	0.15	0.16	0.36	15	140.0	0.21	0.20	0.04	2	-81.0
Brazil	0.34	0.54	0.71	148	108.8	0.95	0.91	0.78	162	-17.9
Canada (2010–2013)	1.18	1.48	2.13	108	80.5	0.20	0.08	0.08	4	-60.0
Chile	0.52	0.74	0.89	18	71.2	0.24	0.15	0.14	3	-41.7
Colombia	0.87	1.22	1.01	48	16.1	0.30	0.20	0.15	7	-50.0
Mexico	1.00	1.26	1.26	123	26.0	0.31	0.22	0.13	13	-58.1
Puerto Rico	0.75	0.55	0.85	4	13.3	0.11	0.08	0.20	1	81.8
USA	1.13	1.31	1.69	751	49.6	0.16	0.12	0.13	58	-18.8
Venezuela (2010–2013)	0.68	0.65	0.82	20	20.6	0.22	0.12	0.12	3	-45.5
Australasian countries										
Hong Kong SAR (2001–2004)	2.35	2.37	2.49	28	6.0	0.11	0.08	0.04	0	-63.6
Israel	0.63	1.20	1.63	14	158.7	0.11	0.07	0.02	0	-81.8
Japan	1.02	0.99	0.96	190	-5.9	1.91	1.59	1.38	281	-27.7
Australia (2006–2009)	1.43	1.82	2.00	60	39.9	0.20	0.10	0.06	2	-70.0
New Zealand (2010–2013)	1.10	1.80	1.55	9	40.9	0.18	0.38	0.16	1	-11.1

Data from 2002 (2000–2004), 2007 (2005–2009) and 2012 (2010–2014) (unless indicated in parentheses). The average number of deaths from the latest period and the corresponding change in rates are provided, according to sex and selected countries. ECC, extrahepatic cholangiocarcinoma; ICC, intrahepatic cholangiocarcinoma.




Fig. 3. Joinpoint analysis of trends in age-standardized (world population) mortality rates from ICC. Data from 24 major countries worldwide, during the period 1995–2016, in men (solid circle) and women (empty circle). ASMR, age-standardized mortality rates; ICC, intrahepatic cholangiocarcinoma.

with the highest rates in East Asia and northern and central Europe.

The reliability and validity of death certification for correctly ascertaining ICC and ECC is possibly affected by diagnostic misclassification between hepatocellular cancers, other liver neoplasms, gallbladder cancers, and between ICC and ECC.⁸ Thus, in our analysis we selected countries with acceptably valid data, according to death certification coverage and population size.

Still, a misclassification between ICC and hepatocellular carcinoma is possible, particularly in cirrhotic patients in whom a biopsy was not performed. While we recognize that using the more granular anatomic classification of intrahepatic, perihilar or distal may have additional clinical implications,²¹ we were limited to the classification system used by most countries.

Mortality trends from ICC and ECC may have been influenced by changes in classification of these neoplasms. Before the

Table 3. Joinpoint analysis for intrahepatic cholangiocarcinoma at all ages, from 1995 to 2016 (according to data availability), by country and sex.

	Period 1	APC 1	Period 2	APC 2	Period 3	APC 3	Period 4	APC 4
Men								
Europe								
Austria	2002–2016	2.4 ¹						
Belgium	2000–2015	4.7 ¹						
Czech Republic	1995–2016	2 ¹						
France	2000–2014	5.4 ¹						
Germany	1998–2007	12.9 ¹	2007–2015	0.5				
Hungary	1996–2016	4.4 ¹						
Italy	2003–2012	7 ¹	2012–2015	-0.5				
Netherlands	1996–2016	5.9 ¹						
Portugal	2002–2014	7.6 ¹						
Spain	1999–2015	5.3 ¹						
Sweden	1997–2016	5.2 ¹						
Switzerland	1995–2015	3.9 ¹						
UK	2000–2015	5 ¹						
The Americas								
Argentina	1997–2007	1.8	2007–2013	22.1 ¹	2013–2015	-10.4		
Brazil	1996–2015	7.1 ¹						
Canada	2000–2013	5.8 ¹						
Chile	1997–2015	10.4 ¹						
Colombia	1997–2015	4.8 ¹						
Mexico	1998–2015	2.5 ¹						
USA	1999–2004	5.1 ¹	2004–2007	0.9	2007–2013	4.9 ¹	2013–2015	0.7
Venezuela	1996–2013	2.9 ¹						
Australasia								
Hong Kong	2001–2013	0.6	2013–2015	-9.3				
Japan	1995–2001	5.9 ¹	2001–2015	0.2				
Australia	1998–2015	4.6 ¹						
Women								
Europe								
Austria	2002–2016	1.4						
Belgium	2000–2015	3.3 ¹						
Czech Republic	1995–2016	2.9 ¹						
France	2000–2008	7.5 ¹	2008–2014	3.1 ¹				
Germany	1998–2000	34.1 ¹	2000–2009	9.1 ¹	2009–2015	-0.8		
Hungary	1996–2005	-4.3	2005–2016	8.7 ¹				
Italy	2003–2015	5.3 ¹						
Netherlands	1996–2007	0.6	2007–2016	9.9 ¹				
Portugal	2002–2014	7.7 ¹						
Spain	1999–2015	4.6 ¹						
Sweden	1997–2016	5.5 ¹						
Switzerland	1995–2015	3.8 ¹						
UK	2000–2015	5.8 ¹						
The Americas								
Argentina	1997–2015	9 ¹						
Brazil	1996–2006	10.5 ¹	2006–2015	4.6 ¹				
Canada	2000–2013	7.5 ¹						
Chile	1997–2015	9.7 ¹						
Colombia	1997–2005	5.9 ¹	2005–2008	16	2008–2011	-9.3	2011–2015	5.8 ¹
Mexico	1998–2015	2.8 ¹						
USA	1999–2015	3.9 ¹						
Venezuela	1996–2013	2.4 ¹						
Australasia								
Hong Kong	2001–2015	0.5						
Japan	1995–2001	4.8 ¹	2001–2015	-0.3				
Australia	1998–2015	5.4 ¹						

APC, annual percentage change.

¹ Significantly different from zero ($p < 0.05$).

2000s, cases of hilar cholangiocarcinoma, called “Klatskin” cancer, were often classified as ICC instead of ECC. However, “Klatskin” tumours are relatively uncommon (e.g. 7% of cholangiocarcinoma in the US) and mortality from ICC progressively increased over recent calendar periods, even after correctly classifying hilar cholangiocarcinoma as ECC.^{8,9,22}

More generally, improvements in diagnostic techniques could partly explain the increases in ICC, i.e. better classification of different forms of intrahepatic neoplasms.⁹ With reference to incidence, an analysis of data from the North American Association of Central Cancer Registries, covering the period from 1999 to 2013, reported an increase in ICC across sexes and

racial/ethnic groups, and a smaller increase in ECC.²³ Despite recent advances in the surgical management of this neoplasm, the prognosis remains poor.^{3,24,25}

The divergent mortality trends observed for ICC and ECC suggest that they have at least partially different etiologies.²³ Only a few studies have investigated the epidemiology of ICC and ECC separately. Available data indicate that these neoplasms may share several risk factors, albeit with differences at least in quantitative terms.^{4–6} A US record-linkage study based on the Surveillance, Epidemiology, and End Results (SEER)-Medicare dataset⁵ found a positive association with hepatitis B virus (HBV) and hepatitis C virus (HCV) mostly for ICC. An association between HCV infection and increased risk of ICC but not ECC was also reported in a large cohort study from the USA.²⁶ Likewise, tobacco smoking, alcohol consumption and non-alcoholic fatty liver diseases (NAFLD) were more strongly associated with ICC, whereas most bile duct conditions tended to be more strongly related with ECC.^{4,5}

Knowledge of risk factors helps to explain ICC trends, which showed a levelling off over recent years in France and Italy, *i.e.* countries that experienced a decrease in alcohol-related chronic liver disease and cirrhosis in the recent past. In contrast, ICC rates increased in other countries, including most European and American countries, which over recent calendar periods showed increases in the prevalence of HCV infection, heavy alcohol consumption, obesity, and NAFLD.^{27,28} Liver flukes (*i.e.*, *Opisthorchis viverrini* and *Clonorchis sinensis*) are a known cause of ICC and ECC in South East Asia.²⁹ They may have somewhat influenced rates in Hong Kong, but are unlikely to be important causes of these diseases in the other countries examined in this study.

Cirrhosis is a strong determinant and pathogenic link to liver cancer.³⁰ However, on the basis of death certification, no information was available on cirrhosis.

A plausible explanation for the generalized decrease in ECC mortality is the increasing use of cholecystectomy, facilitated by laparoscopic techniques over the last decades,³¹ given the known strong association between gallstones and the risk of ECC including gallbladder cancer. Given the low ECC rates, they may be more susceptible to misclassification of Klatskin and gallbladder tumours than ICC. A previous study showed that in the US, after correcting for misclassification of Klatskin, the incidence of ECC may be stable or increasing slightly.⁸ The less strong association of ECC than ICC with major liver diseases and cancer risk factors, such as HBV and HCV infections, alcohol, and NAFLD is also compatible with more favourable incidence and mortality trends of ECC. Still, primary sclerosing cholangitis is also a relevant risk factor, particularly for ECC in the USA and northern Europe.³² Thus, at least part of the fall in ECC mortality in those countries may reflect improved management of primary sclerosing cholangitis.

In conclusion, our study provides strong confirmatory evidence on a global increase in mortality from ICC, whose causes need to be better understood by conducting targeted investigations. Such studies should consider ICC separately from ECC.

Financial support

This work was conducted with the contribution of the Italian Association for Cancer Research (AIRC, project N. 18440), and MIUR (Ministero dell'Istruzione, dell'Università e della Ricerca), with a SIR (Scientific Independence of Young Researchers) 2014

grant (project RBSI1465UH). GC was supported by AIRC Fellowship for Italy “Laura Dubini” (N. 22719).

Conflict of interest

The authors declare no conflicts of interest that pertain to this work.

Please refer to the accompanying ICMJE disclosure forms for further details.

Authors' contributions

Study concept: Carlo La Vecchia and Paolo Boffetta. Study design, acquisition and analysis of the data, and drafting the manuscript: Paola Bertuccio. Critical revision of the manuscript for important intellectual content: all authors.

Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.jhep.2019.03.013>.

References

- [1] Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. *Hepatology* 2011;54:173–184.
- [2] Bergquist A, von Seth E. Epidemiology of cholangiocarcinoma. *Best Pract Res Clin Gastroenterol* 2015;29:221–232.
- [3] Esnaola NF, Meyer JE, Karachristos A, Maranki JL, Camp ER, Denlinger CS. Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma. *Cancer* 2016;122:1349–1369.
- [4] Cardinale V, Semeraro R, Torrice A, Gatto M, Napoli C, Bragazzi MC, et al. Intra-hepatic and extra-hepatic cholangiocarcinoma: new insight into epidemiology and risk factors. *World J Gastrointest Oncol* 2010;2:407–416.
- [5] Petrick JL, Yang B, Altekruse SF, Van Dyke AL, Koshiol J, Graubard BI, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based study in SEER-Medicare. *PLoS ONE* 2017;12 e0186643.
- [6] Welzel TM, Graubard BI, El-Serag HB, Shaib YH, Hsing AW, Davila JA, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. *Clin Gastroenterol Hepatol* 2007;5:1221–1228.
- [7] Khan SA, Emadossadaty S, Ladep NG, Thomas HC, Elliott P, Taylor-Robinson SD, et al. Rising trends in cholangiocarcinoma: is the ICD classification system misleading us? *J Hepatol* 2012;56:848–854.
- [8] Tyson GL, Ilyas JA, Duan Z, Green LK, Younes M, El-Serag HB, et al. Secular trends in the incidence of cholangiocarcinoma in the USA and the impact of misclassification. *Dig Dis Sci* 2014;59:3103–3110.
- [9] Welzel TM, McGlynn KA, Hsing AW, O'Brien TR, Pfeiffer RM. Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. *J Natl Cancer Inst* 2006;98:873–875.
- [10] Patel T. Worldwide trends in mortality from biliary tract malignancies. *BMC Cancer* 2002;2:10.
- [11] Bertuccio P, Bosetti C, Levi F, Decarli A, Negri E, La Vecchia C. A comparison of trends in mortality from primary liver cancer and intrahepatic cholangiocarcinoma in Europe. *Ann Oncol* 2013;24:1667–1674.
- [12] Utada M, Ohno Y, Tamaki T, Sobue T, Endo G. Long-term trends in incidence and mortality of intrahepatic and extrahepatic bile duct cancer in Japan. *J Epidemiol* 2014;24:193–199.
- [13] World Health Organization Statistical Information System. WHO mortality database. Geneva: World Health Organization, 2014. Available from: http://www.who.int/healthinfo/statistics/mortality_rawdata/en/index.html [Accessed 2018 Apr 20].
- [14] World Health Organization. International Statistical Classification of Disease and related Health Problems: 10th revision. Geneva: World Health Organization; 1992.

- [15] Mathers CD, Fat DM, Inoue M, Rao C, Lopez AD. Counting the dead and what they died from: an assessment of the global status of cause of death data. *Bull World Health Organ* 2005;83:171–177.
- [16] World Health Organization Statistical Information System. Health statistics and health information systems. WHO mortality database: Tables. Estimated coverage of mortality data. Available from: <https://www.who.int/healthinfo/statistics/morttables/en/> [Accessed 2018 Apr 20].
- [17] Pan American Health Organization (PAHO). Regional Core Health Data Initiative. Table Generator System. Available from: <http://www.paho.org/English/SHA/coredata/tabulator/newTabulator.htm> [Accessed 2018 Apr 20].
- [18] Doll R, Smith PG. Comparison between registries: age-standardized rates. Vol. IV. IARC Sci Publ No. 42.. Lyon: Cancer incidence in five continents IARC; 1982. p. 671–675.
- [19] Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. (Erratum in: *Stat Med* 2001;20: 655). *Stat Med* 2000;19:335–351.
- [20] National Cancer Institute. Joinpoint Regression Program, version 4.1. Available from: <http://srab.cancer.gov/joinpoint/> [Accessed 2015 Mar 10]
- [21] Razumilava N, Gores GJ. Classification, diagnosis, and management of cholangiocarcinoma. *Clin Gastroenterol Hepatol* 2013;11, 13–21.e1.
- [22] Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. *Hepatology* 2001;33:1353–1357.
- [23] Van Dyke AL, Shiels MS, Jones GS, Pfeiffer RM, Petrick JL, Beebe-Dimmer JL, et al. Biliary tract cancer incidence and trends in the United States by demographic group, 1999–2013. *Cancer* 2019. <https://doi.org/10.1002/cncr.31942>.
- [24] Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM. Treatment and Prognosis for Patients With Intrahepatic Cholangiocarcinoma: Systematic Review and Meta-analysis. *JAMA Surg* 2014;149:565–574.
- [25] Waisberg DR, Pinheiro RS, Nacif LS, Rocha-Santos V, Martino RB, Arantes RM, et al. Resection for intrahepatic cholangiocellular cancer: new advances. *Transl Gastroenterol Hepatol* 2018;3:60.
- [26] El-Serag HB, Engels EA, Landgren O, Chiao E, Henderson L, Amaratunge HC, et al. of hepatobiliary and pancreatic cancers after hepatitis C virus infection: a population-based study of U.S. veterans. *Hepatology* 2009;49:116–123.
- [27] La Vecchia C, Bosetti C, Bertuccio P, Castro C, Pelucchi C, Negri E. Trends in alcohol consumption in Europe and their impact on major alcohol-related cancers. *Eur J Cancer Prev* 2014;23:319–322.
- [28] Jepsen P, Turati F, La Vecchia C. NAFLD and cancer: More cause for concern? *J Hepatol* 2018;68:10–12.
- [29] Choi BI, Han JK, Hong ST, Lee KH. Clonorchiasis and cholangiocarcinoma: etiologic relationship and imaging diagnosis. *Clin Microbiol Rev* 2004;17:540–552.
- [30] La Vecchia C, Negri E, Cavalieri d'Oro L, Franceschi S. Liver cirrhosis and the risk of primary liver cancer. *Eur J Cancer Prev* 1998;7:315–320.
- [31] Nordenstedt H, Mattsson F, El-Serag H, Lagergren J. Gallstones and cholecystectomy in relation to risk of intra- and extrahepatic cholangiocarcinoma. *Br J Cancer* 2012;106:1011–1015.
- [32] Choi J, Ghazizadeh HM, Peerapattit T, Baichoo E, Addissie BD, Harmsen WS, et al. Aspirin use and the risk of cholangiocarcinoma. *Hepatology* 2016;64:785–796.